This shifting landscape, fueled by the rapid expansion of GCCs, AI, cybersecurity, renewable energy, fintech, and digital ...

Roland Wandeler will succeed Jean-Paul Clozel, MD, who has been serving as ad-interim CEO since March 2026 and will continue in his role as Chairman of the Board of Directors. Jean-Paul Clozel will ...

Publication volumes are one of the main ways that success is measured for researchers today. From mentorship to real-world ...

CRISPR Therapeutics is a gene editing specialist. It developed Casgevy, a medicine for two rare blood diseases, in collaboration with Vertex Pharmaceuticals. Casgevy doesn't generate much revenue yet, ...

These two drugmakers are highly innovative. They have important catalysts on the horizon. 10 stocks we like better than CRISPR Therapeutics › The biotech industry is on fire right now. Over the past ...

Be Biopharma’s terminated trial is the latest setback in the hemophilia space, where companies like Pfizer and BioMarin have opted to pull their respective products from the market after weak traction ...

Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Soligenix has scrapped its cutaneous T-cell lymphoma (CTCL) program in the wake of a phase 3 setback, leaving the biotech focused on another rare disease prospect and considering strategic ...